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Abstract
Background: Angiotensin receptor blockers (ARBs) are commonly used as a treatment for many cardiovascular
diseases, but their safety has been called into question. The VALUE trial found an increased risk of myocardial
infarction in participants receiving ARBs compared to other antihypertensive. The aim of the meta-analysis was to
synthetize the available evidence of randomised controlled trials (RCTs) and elucidate if ARBs increase the risk of
cardiovascular events.
Methods: A comprehensive search was conducted to identify RCTs that assessed the safety of ARBs. Titles and
abstracts of all papers were independently screened by two authors. Data extraction and quality assessment were
also performed independently. The relative risk (RR) of all-cause mortality, myocardial infarction, and stroke were
pooled using the IVhet model. Multiple sensitivity analyses were conducted to assess the effect of ARBs by
restricting the analysis to different participants’ characteristics.
Results: Forty-five RCTs comprising of 170,794 participants were included in the analysis. The pooled estimates
revealed that ARBs do not increase the risk of all-cause mortality (RR 1.00; 95%CI 0.97–1.04), myocardial infarction
(RR 1.01; 95%CI 0.96–1.06), and stroke (RR 0.92; 95%CI 0.83–1.01). The sensitivity analysis did not yield a particular
group of patients at increased risk of cardiovascular events with ARBs. Risk of all-cause mortality and stroke
decreased with ARB when the proportion of smokers in a population was < 25% (RR 0.91; 95%CI 0.84–0.98) and in
females (RR 0.76; 95%CI 0.68–0.84), respectively.
Conclusions: ARBs do not increase the risk of major cardiovascular events and are safe for use in patients.
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Background
Cardiovascular diseases (CVDs) remain one of the most
prevalent non-communicable diseases and impose a
great burden on the healthcare systems. Globally, an es-
timated 16.7 million deaths in the year 2010 were attrib-
uted to CVD with projections showing a staggering 23.3
million deaths by 2030 [1]. Hypertension is the leading
risk factor for CVD and it is associated with 57 million
disability adjusted life years (DALYs) worldwide [2].
It is well known that the risk of major cardiovascular
events can be reduced by a wide spectrum of antihyper-
tensive drugs including angiotensin receptor blockers
(ARBs) [3]. This type of drug works by inhibiting the
angiotensin II receptors, thus causing systemic vasodila-
tation, thereby aiding in the reduction of blood pressure
[4]. ARBs are one of the most common drugs used for
controlling blood pressure, treating heart failure, and
preventing kidney failure in people with diabetes or
hypertension [5]. However, the safety of ARBs in com-
parison to other anti-hypertensive medications has been
called into question.
The VALUE trial found that ARBs (valsartan) in-
creased the risk of myocardial infarction (fatal and non-
fatal) by 19% compared with calcium channel blockers
(amlodipine) [6]. This observation led many researchers
to examine cautiously the evidence surrounding ARBs
and myocardial infarction. For example, the point esti-
mate of the CHARM-alternative trial suggests a 36% in-
crease in myocardial infarction with candesartan (versus
placebo) regardless of the reduction in blood pressure
[7]. On the other hand, the TRANSCEND trial found an
8% decrease in risk of cardiovascular admissions for
those on telmisartan compared to placebo [8].
Angiotensin-converting-enzyme (ACE) inhibitors are
known to have a cardioprotective effect and the safety
profile of ACE inhibitors have been shown not to differ
from ARBs [9]. Hence it was unclear the mechanism
that could explain an increase in risk of myocardial in-
farction with ARBs. Due to the wide use of ARBs for
many CVDs and the contradictory results, we decided to
conduct a systematic review and meta-analysis of rando-
mised controlled trials (RCTs) to elucidate the cardio-
vascular safety profile of ARBs.
Methods
Findings of this systematic review and meta-analysis are
presented according to PRISMA reporting guidelines
[10].
Search strategy and selection criteria
A systematic search was conducted in PubMed in Sep-
tember 2018. The following search terms were included:
randomized controlled trial, angiotensin receptor antag-
onist, cardiovascular disease, and mortality. The full
search strategy is shown in the supplementary material
(S1). To achieve a comprehensive evaluation of the pub-
lished evidence, the systematic search was supplemented
with a similarity search (i.e. the first 20 related citations
of each included paper) as well as hand search of the ref-
erence lists of relevant studies. Titles and abstracts were
uploaded on Rayyan (http://rayyan.qcri.org/) [11] for the
screening process. Two authors (YW and RB) independ-
ently screened all the records by title and abstract. Dis-
agreements were resolved through author consensus and
involvement of a third author (LFK).
Fig. 1 PRISMA flow diagram of study selection
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The inclusion of studies was restricted to human stud-
ies; RCTs comparing ARBs versus a control (either a
placebo or another antihypertensive medication); follow-
up of at least 12 months; and reported all-cause mortal-
ity, myocardial infarction, and stroke as outcomes. Re-
current myocardial infarction and stroke were also
considered if the study only included patients that have
had recently experienced myocardial infarction or stroke.
Observational studies, studies where ARBs were not the
first line of treatment, and conference abstracts were
excluded.
Data extraction and quality assessment
The number of participants and the number events (i.e.
all-cause mortality, myocardial infarction, and stroke) in
each intervention group (ARBs [active] and non-ARBs
[control]) were extracted. In addition, study characteris-
tics (e.g. study sites and follow-up period) and partici-
pants’ characteristics (e.g. mean age, proportion of
males, mean BMI) were extracted. The Cochrane Collab-
oration’s tool for assessing risk of bias in randomized tri-
als [12] was used to assess the risk of bias of the
included studies.
Statistical analysis
The outcomes of interest were the relative risks (RRs) of
all-cause mortality, myocardial infarction, and stroke
with ARBs compared to the control group. The inverse
variance heterogeneity (IVhet) model was used to pool
the effect size [13]. The I2 index was used to assess
heterogeneity among studies, an I2 > 50% was considered
significant heterogeneity.
Sensitivity analyses were conducted to identify poten-
tial scenarios where ARBs increase the risk of all-cause
mortality, myocardial infarction, and stroke. The follow-
ing analyses restricting the meta-analysis to: control
group (active medication, only ACE inhibitors, or pla-
cebo); follow-up period (≤40 weeks or > 40 weeks); pro-
portion of males (≤50% or > 50%); age (≤65 years or > 65
years); BMI (normal range or overweight/obese); ele-
vated total cholesterol (≥200 mg/dL); elevated LDL
(≥120 mg/dL); decreased HDL (< 50mg/dL); elevated tri-
glyceride (≥150 mg/dL); proportion of smokers (< 25%
or ≥ 25%); only patients with hypertension; only patients
with or without chronic heart failure; only patients with
or without diabetes mellitus; only patients with ische-
mic/coronary artery disease; and only patients with
chronic kidney disease.
Publication bias was assessed through visual inspection
of funnel and Doi plots and statistically through the
Egger’s regression p-value and the LFK index [14]. All
the analyses were conducted in Stata MP 14 (StataCorp,
College Station, TX, USA).
Result
Study selection and study characteristics
One thousand seven hundred and eighty-six unique re-
cords were identified through the search strategy and
the similarity search. Four hundred and seventy-four re-
cords remained after the title and abstract screening and
44 publications remained after the full-text screening.
Fig. 2 Forest plot depicting the relative risk of ARBs on a) all-cause mortality, b) myocardial infarction, and c) stroke
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Table 2 Sensitivity analyses
All-cause mortality Myocardial infarction Stroke
RR (95%CI) I2 N RR (95%CI) I2 N RR (95%CI) I2 N
Type of control
Placebo 0.99 (0.95–1.04) 13 18 0.96 (0.88–1.05) 0 14 0.91 (0.85–0.98) 7 14
Active 1.01 (0.95–1.08) 28 21 1.03 (0.96–1.11) 7 23 0.93 (0.79–1.08) 54 22
Active only ACE inhibitors 1.04 (0.95–1.13) 46 8 1.01 (0.93–1.09) 0 9 0.98 (0.88–1.10) 0 8
Follow-up period
≤ 40 weeks 1.01 (0.91–1.14) 51 19 0.98 (0.88–1.10) 12 18 0.94 (0.74–1.20) 40 18
> 40 weeks 1.00 (0.96–1.03) 0 20 1.03 (0.96–1.10) 0 19 0.90 (0.82–1.00) 45 18
Proportion of males
≤ 50% 0.93 (0.86–1.00) 0 6 1.02 (0.85–1.22) 37 5 0.76 (0.68–0.84) 0 5
> 50% 1.02 (0.97–1.06) 23 33 1.01 (0.95–1.07) 0 32 0.96 (0.87–1.05) 28 31
Age
≤ 65 years 0.98 (0.88–1.09) 32 18 0.95 (0.85–1.06) 0 15 1.03 (0.80–1.34) 22 12
> 65 years 1.01 (0.98–1.05) 10 20 1.04 (0.98–1.10) 0 21 0.92 (0.84–1.00) 41 23
BMI
Normal range 0.84 (0.60–1.19) 31 7 0.81 (0.41–1.57) 0 6 1.21 (0.77–1.90) 0 5
Overweight and obese 1.01 (0.98–1.04) 0 24 1.01 (0.96–1.07) 5 24 0.92 (0.83–1.01) 49 23
Elevated total cholesterol
≥ 200mg/dL 0.98 (0.91–1.05) 15 10 0.99 (0.91–1.08) 0 8 0.82 (0.74–0.91) 6 7
Elevated LDL
≥ 120mg/dL 1.01 (0.90–1.14) 36 7 0.97 (0.87–1.07) 0 6 0.86 (0.70–1.07) 45 5
Decreased HDL
< 50 mg/dL 1.01 (0.95–1.08) 15 11 0.99 (0.89–1.09) 20 10 0.90 (0.82–0.98) 0 8
Elevated triglyceride
≥ 150mg/dL 1.01 (0.94–1.08) 13 8 0.99 (0.90–1.09) 16 8 0.92 (0.83–1.01) 0 7
Proportion of smokers
< 25% 0.91 (0.84–0.98) 2 12 0.99 (0.88–1.11) 0 13 0.81 (0.67–0.99) 41 12
≥ 25% 0.99 (0.95–1.05) 7 15 0.99 (0.91–1.01) 0 12 0.92 (0.87–0.98) 0 12
Hypertension
Only patients with hypertension 0.98 (0.89–1.07) 0 12 1.02 (0.80–1.29) 27 12 0.82 (0.66–1.03) 57 13
Chronic heart failure (CHF)
Only patients without CHF 0.97 (0.92–1.03) 0 11 0.99 (0.83–1.18) 43 12 0.85 (0.73–1.00) 47 11
Only patients with CHF 1.00 (0.85–1.19) 75 6 1.06 (0.86–1.32) 0 8 1.04 (0.81–1.32) 14 8
Diabetes mellitus (DM)
Only patients without DM 0.99 (0.38–2.61) 0 2 0.65 (0.26–1.59) 48 3 0.72 (0.50–1.04) 37 3
Only patients with DM 1.04 (0.88–1.23) 0 7 0.99 (0.53–1.80) 67 4 1.31 (0.73–2.35) 30 3
Ischemic/coronary artery disease
Only patients with ischemic/coronary artery disease 1.06 (0.91–1.22) 25 7 0.97 (0.88–1.07) 0 7 1.02 (0.84–1.24) 0 5
Chronic kidney disease
Only patients with chronic kidney disease 0.86 (0.66–1.12) 50 8 0.99 (0.71–1.41) 20 9 1.08 (0.83–1.39) 0 8
CI confidence interval; N number of studies; RR relative risk; ACE angiotensin-converting-enzyme
Statistically significant results are emboldened
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The 44 publications reported data from 45 RCTs and
170,794 participants (85,544 participants in the ARB
group and 85,250 participants in the placebo/control
group) (Fig. 1). The publication by Chaturvedi et al. [15]
reported findings from two RCTs, the DIRECT-Prevent
1 and DIRECT-Protect 1 studies.
Twenty four RCTs compared ARBs versus placebo,
while 21 RCTs against an active medication. The majority
of RCTs (n = 39) included a larger proportion of males
(ranging from 54 to 90%). Only two RCTs, DIRECT-
Prevent 1 and DIRECT-Protect 1 enrolled participants
with a median age < 50 years. Among the studies that re-
ported the median BMI, only 22% had participants with a
normal BMI (< 25 kg/cm2). Fourteen, nine, and eight
RCTs included only patients with hypertension, chronic
heart failure, and diabetes mellitus, respectively (Table 1).
All-cause mortality, myocardial infarction, and stroke were
assessed in 39, 37, and 36 RCTs.
Quantitative synthesis
After pooling all the available evidence, it was found that
ARBs do not increase the risk of all-cause mortality (RR
1.00; 95%CI 0.97–1.04), myocardial infarction (RR 1.01;
95%CI 0.96–1.06), or stroke (RR 0.92; 95%CI 0.83–1.01)
(Fig. 2). Sensitivity analyses based on different study and
participants characteristics showed no increase in risk of
any of the three outcomes of interest. However, it was
also noticed that ARBs did not reduce the risk of all-
cause mortality (RR 0.99; 95%CI 0.95–1.04) or myocar-
dial infarction (RR 0.96; 95%CI 0.88–1.05) when com-
pared to placebo, ARBs only decreased the risk of stroke
(RR 0.91; 95%CI 0.85–0.98) (Table 2). Sensitivity ana-
lyses also revealed a decreased in all-cause mortality risk
with ARBs when the proportion of smokers is small (<
25%) (RR 0.91; 95%CI 0.84–0.98); and stroke in females
(RR 0.76; 95%CI 0.68–0.84), patients with elevated total
cholesterol (RR 0.82; 95%CI 0.82–0.91) and lower levels
of HDL (RR 0.90; 95%CI 0.80–0.98) (Table 2).
The most common deficiencies were no blinding of
participants and personnel (n = 14; 31%), followed by no
blinding of the outcome assessor (n = 10; 22%) and in-
complete outcome data (n = 10; 22%). Overall, the RCTs
showed low risk of bias except for E-COST [25], E-
COST-R [26], and Kondo et al. [36] (S2).
The Doi plots revealed minor asymmetry for all-cause
mortality (LFK index = − 1.24) and myocardial infarction
(LFK index = − 1.33) for RCTs reporting favourable re-
sults for ARBs. No asymmetry was observed for stroke
(supplementary material S3).
Discussion
Findings from previous RCTs were controversial, the
VALUE [6] and the CHARM-alternative [7] trials found
increase in myocardial infarction with ARBs compared
to amlodipine and placebo, respectively. While other
large RCTs such as the LIFE [38] and the RENAAL [46]
trials found a decrease in all-cause of death and myocar-
dial infarction with ARBs. In 2011, Bangalore et al. [57]
conducted a meta-analysis on ARBs and the risk of myo-
cardial infarction and found that ARBs do not increase
the risk of cardiovascular events. Since then, multiple
RCTs have been published; in our meta-analysis we
pooled the most updated evidence (45 RCTs comprising
of 170,794 participants – 8 RCTs and 23,000 more par-
ticipants that Bangalore et al.) and corroborated that
ARBs are safe medications as they do not increase the
risk of all-cause mortality, myocardial infarction, or
stroke. It is worth pointing out that our meta-analysis
(in line with previous studies [57, 58]) also found that
ARBs do not reduce the risk of all-cause mortality and
myocardial infarction when compared to placebo.
In addition, the safety profile of ARBs was examined
in multiple scenarios by restricting the analysis to differ-
ent study and participants characteristics (i.e. sensitivity
analyses). In none of the cases, ARBs were found to in-
crease the risk of all-cause mortality, myocardial infarc-
tion, and stroke. ARBs reduce the risk of all-cause
mortality by 9% in populations with low prevalence of
smokers and exerts a cerebrovascular protective effect in
female patients and patients with abnormal total choles-
terol or HDL.
Findings from our study are reassuring for patients
and clinicians as ARBs are widely used to treat condi-
tions such as hypertension, chronic kidney disease/kid-
ney failure (especially in patients with diabetes mellitus),
and heart failure. However, the findings need to be
understood in light of some of the limitations. Only
RCTs were included, but the possibility of confounding
not accounted during the analysis of the RCTs cannot
be completely ruled out. There was heterogeneity in the
RCTs protocols (e.g. inclusion criteria, different ARBs,
different doses, follow-up) that needs to be accounted in
future research synthesis studies through individual pa-
tients meta-analysis.
Conclusion
In conclusion, our meta-analysis provides reassuring evi-
dence for patients and clinicians that ARBs are safe
drugs, and do not increase the risk of death, myocardial
infarction, and stroke.
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